6 May 2015

Plethora treatment wins NHS approval

15/04/2011 Ben Jaglom

Specialist pharmaceutical concern Plethora Solutions Holdings (PLE) says it has won approval for its vaginal dryness treatment Hyalofemme from the NHS for prescription.

The agreement means that doctors in the UK will now be able to write prescriptions for Hyalofemme for the first time for atrophic vaginitis, commonly referred to as vaginal dryness. Traditional treatments involve the use of hormonal creams containing estrogen, but such creams are often inappropriate for cancer patients, who often suffer vaginal dryness as a side effect of cancer treatment.

Chairman Bill Robinson remarks the decision by the NHS should 'increase the commercial value of our pipeline by exploiting products secured last year'. He adds that the release of Hyalofemme is an 'important treatment' for atrophic vaginitis.

Following the announcement analysts at house broker Daniel Stewart held their forecasts of a year-end loss of £1.3 million (2010: loss of £1.5 million) on revenue up £100,000 to £1.2 million. They have pencilled in a loss per share of 2.5p for 2011 and a further loss of 3.4p a share for 2012.

Shares in Plethora were up 0.25p this morning following the announcement to 7.5p, the price at which Growth Company Investor recommended them earlier this month. A good sign for the company's prospects, Hyalofemme will be prescribed both for those being treated for cancer and women going through the menopause. We therefore reiterate our speculative buy rating.

Tags: AIM market, Menopause, Pharma, Plethora Solutions Holdings, Urology Company, Vaginal dryness

Superb investment toolkit for private investors

SharePad is the new web-based service from ShareScope. Easier to use and more powerful. Perfect for tablets, Macs and Windows PC. Covers ALL your investment requirements.

Growth Company Investor: free trial

Since 2008, our share tips outperformed the benchmark by 281%. Take a free trial and get access to our recommendations today. Start free trial now.

Directors' Pay on AIM 2015

The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

Riyadh has seen a flurry of building activity of late

New Action hotel in Saudi 23/04/2015

Middle Eastern hotel specialist Action Hotels (AIM:AHCG) is planning a new hotel in Riyadh, Saudi Arabia.

Tags: Hotels, Saudi Arabia

21st Century makes win 23/04/2015

CCTV specialist 21st Century Technology (AIM:C21) has won a new contract to supply its services.

Tags: Contract win, Technology

Victoria gaining power 23/04/2015

Cameroon-focused Victoria Oil and Gas (AIM:VOG) has begun supplying power to the Logbaba station.

Tags: Oil and gas, West Africa

Ultrasis calls in administrators 22/04/2015

Ultrasis, a developer of treatments for anxiety and depression, has had to call in administrators after its fundraising efforts failed.

Tags: Administrators, Business closing, Feeling depressed

McKay pays £11m for warehouse 22/04/2015

Office space investor McKay Securities (LON:MCKS) has purchased a warehouse unit for just under £11 million.

Tags: Real estate

Creston feels more splendid 22/04/2015

Media agency Creston (LON:CRE) has acquired digital consultant How Splendid in a deal worth up to £15.7 million.

Tags: Acquisitions, Media

More News